TABLE 5.
Inhibitory concentrations of (+)-DMJ-II-121 and the 17b antibody (alone and in the presence of (+)-DMJ-II-121), tested against HIV-1 JR-FL, transmitted/founder viruses, and A-MLVa
| Virus | IC50 of: |
||
|---|---|---|---|
| (+)-DMJ-II-121 (μM) | 17b (μg/ml) | 17b + 50 μM (+)-DMJ-II-121 (μg/ml) | |
| JR-FL | 48.8 ±7.8 | >100 | 0.6 ± 0.0 |
| 4F12 | 4.5 ± 2.2 (n = 2) | >100 (n = 2) | 25.2 ± 24.2 (n = 2) |
| TC4 | 0.9 ± 0.3 | 67.4 ± 32.6 | 34.0 ± 33.0 |
| TD12 | 7.1 ± 2.2 | >100 | <1 |
| TA11 | 3.3 ± 2.7 (n = 2) | >100 (n = 2) | 3.7 ± 2.7 (n = 2) |
| D3 | 59.3 ± 15.9 (n = 2) | >100 (n = 2) | 34.2 ± 33.2 (n = 2) |
| B5 | 46.4 ± 27.1 | 70.6 ± 29.4 | 28.3 ± 24.0 |
| 2010 F5 | 67.4 ± 32.6 | >100 | >100 |
| 0363 C3 | 57.9 ± 24.9 | 93.8 ± 6.2 | 76.9 ± 23.2 |
| 1176 A3 | 63.3 ± 15.9 | 21.4 ± 7.3 | 12.2 ± 6.7 |
| 3A1 | 71.4 ± 14.4 | 96.4 ± 3.6 | 62.4 ± 23.1 |
| TA5 | >100 | 78.1 ± 14.7 | >100 |
| A-MLV | >100 | >100 | >100 |
a
The IC50s of (+)-DMJ-II-121 and the 17b antibody [alone and in the presence of 50 μM (+)-DMJ-II-121] are reported. The number of experiments is shown in parentheses; unless indicated, the reported IC50 is derived from 3 to 5 independent experiments.